Taken together, whilst CD11c+ cells from elderly IL-2/CD40-treated mice have increased capacity to present antigens to T cells, their ability to license tumor-specific T cells appears compromised, relative to young counterparts. This evidence concerns the gene IL2 and neoplasm.